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Background/aim: The aim of this study was to evaluate the effects of a 6-month treatment regimen with exenatide on the lipid profile,
high-sensitivity C-reactive protein (hsCRP), carotid intima media thickness (CIMT), visceral adiposity, and nonalcoholic fatty liver
disease (NAFLD), all of which are important cardiovascular risk factors.
Materials and methods: This study included 45 obese patients with type 2 diabetes mellitus (T2DM). Baseline clinical findings,
laboratory parameters, and ultrasonography findings were recorded. An exenatide recipe was given twice daily to the patients and, after
6 months of therapy, the same variables were compared. The compared parameters were lipid profiles, hsCRP, aspartat aminotransferase,
alanine aminotransferase, gamma-glutamyl transferase, liver craniocaudal diameter, visceral fat volume, subcutaneous fat thickness,
and CIMT. Liver diameter, visceral fat volume, subcutaneous fat thickness, and CIMT were measured by ultrasonography.
Results: After therapy, statistically significant improvements were achieved in lipid profile, hsCRP, liver enzymes, body mass index,
and waist and hip circumferences. Also, statistically significant decreases were obtained in liver craniocaudal diameter, subcutaneous
fat thickness, visceral fat volume, and CIMT. The reduction of CIMT and liver diameter were not correlated with BMI and HbA1c
reduction.
Conclusion: This study showed improvement in lipid profile and hsCRP levels with exenatide treatment. We also showed decrease
in both visceral fat volume and subcutaneous fat thickness. We demonstrated significant decrease in liver enzymes with significant
decrease in liver diameter. These findings support the use of exenatide in patients with NAFLD and T2DM. Additionally, this study
showed that exenatide treatment given twice daily reduces CIMT in obese T2DM patients.
Key words: Carotid intima media thickness, hsCRP, nonalcoholic fatty liver disease, subcutaneous fat thickness, visceral fat volume,
lipid profile

1. Introduction
Type 2 diabetes mellitus (T2DM) is an important risk factor
for cardiovascular morbidity and mortality [1]. Patients
with T2DM also frequently exhibit other cardiovascular
risk factors like high blood pressure, dyslipidemia,
nonalcoholic fatty liver disease (NAFLD), obesity, and
visceral adiposity [2–5]. Because of the importance of
cardiovascular events in T2DM, clinicians should focus on
these cardiovascular risk factors. Considering these facts,
the treatment of T2DM should include the aforementioned
cardiovascular risk factors.
Exenatide, a glucagon-like peptide-1 (GLP-1) analogue,
is a commonly used drug for the treatment of T2DM [6].
Exenatide also has beneficial effects other than glisemic

control. Obesity is an important factor in patients with
T2DM, and exenatide has a well-known effect on weight
reduction [7]. Limited studies have shown the favorable
effects of exenatide on NAFLD, visceral adiposity, and
inflammatory markers, all of which are important
cardiovascular risk factors [8–11]. A prospective study
showed that exenatide had a better hepatic protective
effect than intensive insulin therapy in patients with
NAFLD with elevated liver enzymes and T2DM [10]. Du
et al. showed, with computed tomography measurement,
that exenatide decreased visceral adipose tissue without
a reduction in subcutaneous adipose tissue volume [9].
Carotid intima-media thickness (CIMT) is a marker of
atherosclerosis and predicts cardiovascular events [12].
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The effect of exenatide on CIMT has not been widely
investigated to date. An animal study showed that local
subcutaneous injections of exenatide reduced CIMT in
diabetic rats [13] and, recently, it was shown that exenatide
given once weekly significantly improved CIMT [14].
Exenatide reduces tryglyceride levels and increases
high-density lipoprotein (HDL), but its effect on lowdensity lipoprotein (LDL) was found to be controversial in
some studies [9,11]. High-sensitivity C-reactive proteins
(hsCRP) are another marker of cardiovascular risk
prediction, and they decreased after exenatide therapy in
several studies [15].
In this prospective study, we aimed to evaluate the
effects of a 6-month treatment regimen with exenatide on
lipid profile, hsCRP levels, CIMT, visceral adiposity, and
some NAFLD parameters.
2. Methods
This study was a prospective study and included patients
with T2DM who were admitted to our center between
2015 and 2017. All of the patients included in this trial had
a body mass index (BMI) over 35 kg/m2, were over 18 years
old, and were not using exenatide before the study. All
patients were using metformin with/without sulfanylurea
at the beginning of the study. The indication for exenatide
treatment was to achieve glycemic control and to reduce
weigh for better cardiovascular outcomes. Patients who
had drug or dose changes in the 6 months since the
study began were excluded. All patients continued their
prior medical therapy for diabetes, hypertension, and
hyperlipidemia throughout the study period, and patients
who needed a new drug or stopped a medication for any
reason were excluded from statistical analysis. Patients
who had recent cerebrocardiovascular events, renal failure,
severe chronic infections, neoplasms, cardiovascular
diseases (hypotension, uncontrolled hypertension, or
Takayasu arteritis), a history of acute pancreatitis, alcohol
consumption, cirrhosis, and chronic hepatitis were
excluded from the study. Patients who were pregnant or
intended to become pregnant were not included in the
study. All patients underwent laboratory analysis before
the treatment, and patients with the following parameters
were excluded from the study: higher LDL levels than
200 mg/dL, higher triglyceride levels than 400 mg/dL,
lower HDL levels than 30 mg/dL, and higher aspartate
aminotransferase (AST) or alanin aminotransferase (ALT)
levels than 100 U/L. Patients who needed a dose change
of antihypertensive or antihyperlipidemic drugs during
the study were also excluded from the statistical analysis.
All patients with an indication for exenatide and who had
no exclusion criteria were included in the study. After
inclusion in the study, exenatide, at a dose of 5 μg twice a
day, was given, and the dose was increased to 10 μg twice
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daily after 4 weeks. A standard hypocaloric diabetic diet
and regular standard aerobic exercise were prescribed to
all patients. The patients continued their daily dietary and
exercise routines without any limitation.
In terms of baseline demographic data, clinical
characteristic features, and duration of T2DM,
comorbidities and concomitant medications were
recorded. Weight and height were measured, and BMI
was calculated as the weight (kg) divided by the square
of the height (m) at the beginning and after the 6 months
of treatment. All patients underwent laboratory analysis
before treatment and after the 6 months of the study
participation. Fasting blood samples were collected
between 08.00 and 09.00. The measures recorded in the
laboratory analysis included complete blood count (CBC),
creatinine, ALT, AST, gamma-glutamyl transferase (GGT),
fasting plasma glucose (FPG), postprandial plasma glucose
(PPG), glycated hemoglobin (HbA1c), albumin, LDL,
HDL, triglyceride, and hsCRP.
Ultrasonography (US) (Toshiba Aplio Ultrasound
Imaging System, Japan) was performed at the beginning of
the study and after 6 months of exenatide treatment. After
an overnight fasting period, visceral fat was measured in
the supine position. For each patient, 4 measurements
were obtained: 1) the distance between the internal
surface of the splenic vein and the abdominal muscle; 2)
the distance between the internal surface of the abdominal
muscle and the posterior wall of the aorta on the
umbilicus; 3) the thickness of the fat tissue of the posterior
right renal wall in the right posterior perinephric space;
and 4) the thickness of preperitoneal and subcutaneous
fat layers in the xiphoid process [16]. The thickness of the
preperitoneal and subcutaneous fat layers in the xiphoid
process was determined as subcutaneous fat thickness. The
visceral fat volume was calculated as: [visceral fat volume]
= –9.008 + 1.191 × [distance between the internal surface
of the abdominal muscle and the splenic vein (mm)]
+ 0.987 × [distance between the internal surface of the
abdominal muscle and the posterior wall of the aorta on
the umbilicus (mm)] + 3.644 × [thickness of the fat layer
of the posterior right renal wall (mm)] [16]. A 7.5-MHz
linear-array probe was used to measure the thickness of
the subcutaneous and the preperitoneal fat layers, and a
3.75-MHz convex-array probe was used to for all other
measurements. The procedures were performed by the
same investigator. The intraexamination coefficient of
variation for US was 1%. To assess the reliability and
reproducibility of US, 5 participants were selected, and
these measurements were repeated at the same time after
1 day by the same investigator. Within 95% confidence
limits, the intraclass correlation coefficient was 97.6. This
assessment showed the reproducibility and reliability of
our measurements. CIMT was measured by US in the
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supine position by the same experienced radiologist.
High-resolution B-mode US images (Logic 3, General
Electric, USA), using an 11-MHz linear array transducer,
were applied for CIMT measurements. Three arterial wall
segments in each carotid artery were obtained from a fixed
lateral transducer angle at the far wall. The mean CIMT
was calculated from the 3 segments of both carotid arteries.
During the same session, the liver was evaluated for lipid
accumulation, and the maximum craniocaudal diameter
of the liver was then measured. NAFLD was determined
as having a diffuse hyperechoic texture of the liver in
ultrasonography and when other reasons for steatosis,
including alcohol consumption, drug use, and chronic
hepatitis, are excluded. Liver biopsy was not performed in
this study.
The Local Ethics Committee approved the study
design, and methods and written informed consent were
obtained from all participants included in this study.
Statistical analyses were performed with SPSS software
21.0 (SPSS, IBM, Armonk, NY, USA). The Kolmogorov–
Smirnov test was performed to assess the normality of
the distribution of data. Data with normal distribution
variables were expressed as mean ± standard deviation
(SD), and a paired sample t-test was used to compare
values before and after therapy. Data without normal
distribution were expressed as median (interquartile
range), and a Wilcoxon test was used to compare values
before and after therapy. Pearson’s correlation analysis was

used to determine correlation. P-values less than 0.05 were
considered statistically significant.
3. Results
This study included 60 patients during the study
participation, but the final statistical analysis was performed
with 45 patients, including 41 women and 4 men. Eight
patients dropped out of follow-up, and 7 patients had
adverse events (nausea in 5 patients, drug eruption in 2
patients). The mean age of the study participants was 47.91
± 7.30. All of the patients had been using antidiabetic
drugs before the study, and their BMI were over 35 kg/m2.
All of the patients were using metformin before the study
participation, whereas 13 patients were using gliclazide
with metformin.
The laboratory parameters before and after therapy
are summarized in Table 1. Statistically significant
decreases were achieved in triglyceride, total cholesterol,
LDL, hsCRP, AST, ALT, and GGT levels. BMI, waist,
and hip circumference values decreased significantly
with exenatide therapy (Table 2). After exenatide
therapy, statistically significant decreases were obtained
in subcutaneous fat thickness (Figure a), visceral fat
volume (Figure b), liver craniocaudal diameter (Figure
c), and CIMT (Figure d) (Table 2). The mean decrease of
visceral fat volume and subcutaneous fat thickness were
16.08% and 19.08%, respectively. The visceral fat volume/
subcutaneous fat thickness ratio improved from 1.53

Table 1. Laboratory findings before and after exenatide therapy.
Before exenatide
treatment

After exenatide
treatment

P-value

Triglyceride (mg/dL)

174.02 ± 85.52

145.47 ± 50.52

0.019

Total cholesterol (mg/dL)

211.8 ± 43.38

183.23 ± 32.40

<0.001

HDL (mg/dL)

48.77 ± 9.83

51.70 ± 9.62

0.034

LDL (mg/dL)

128.72 ± 38.64

103.00 ± 27.44

<0.001

non-HDL cholesterol (mg/dL)

162.81 ± 40.42

132.63 ± 32.34

<0.001

FPG (mg/dL)

155.13 ± 46.51

117.69 ± 26.10

<0.001

HbA1c (%)

7.80 ± 1.31

6.71 ± 0.92

<0.001

hsCRP (mg/L)

8.66 ± 6.02

5.16 ± 2.85

<0.001

Creatinin (mg/dL)

0.77 ± 0.09

0.74 ± 0.10

0.074

ALT (U/L)

23 (10-99)

19 (11-51)

<0.001

AST (U/L)

20 (12-70)

19 (12-55)

0.005

GGT (U/L)

49.40 ± 17.75

33.78 ± 8.26

<0.001

HDL: high-density lipoprotein; LDL: low-density lipoprotein; FPG: fasting plasma glucose; HbA1c:
glycated hemoglobin; ALT: alanin aminotransferase; AST: aspartate aminotransferase; GGT: gammaglutamyl transferase.
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Table 2. Anthropometric measures and ultrasonographic findings before and after exenatide therapy.
Before exenatide
treatment

After exenatide
treatment

P-value

BMI (kg/m2)

43.46 ± 6.01

39.60 ± 5.63

<0.001

Waist circumference (mm)

126.47 ± 15.10

120.49 ± 15.24

<0.001

Hip circumference (mm)

132.82 ± 12.86

125.96 ± 12.39

<0.001

Liver largest craniocaudal diameter (mm)

188.26 ± 17.41

180.09 ± 16.49

<0.001

Subcutaneous fat thickness (mm)

29.10 ± 5.11

23.49 ± 4.98

<0.001

Visceral fat volume (mm3)

271.52 ± 41.01

227.54 ± 39.42

<0.001

CIMT (mm)

1.04 ± 0.11

0.75 ± 0.12

<0.001

BMI: body mass index; CIMT: carotid intima-media thickness.

± 0.24 to 1.92 ± 0.30 (P = 0.021). All of the patients had
steatosis on US at the beginning of the study. A significant
reduction in the craniocaudal liver diameter was achieved
with treatment (Table 2).
Correlation analysis was performed, and the reduction
of HbA1c, weight, CIMT, liver diameter, subcutaneous
fat thickness, and visceral fat volume were included in
the analysis (Table 3). The reduction of CIMT did not
correlate with BMI and HbA1c reduction. The reduction
of subcutaneous fat thickness and visceral fat volume both
correlated with weight reduction but not with HbA1c.
The reduction of liver diameter only correlated with
subcutaneous fat thickness reduction but not with HbA1c
and weight reduction.
Weight reduction was achieved in 44 patients, and
1 patient had no change in weight. Thirty-five patients
had a weight reduction of more than 5%. When patients
with less than 5% weight reduction were included in
the analysis, CIMT, liver diameter, visceral fat volume,
and subcutaneous fat thickness still showed statistically
significant decreases (P = 0.005, P = 0.005, P = 0.008, P =
0.008, respectively).
4. Discussion
In this study, we investigated the effects of 6 months of
exenatide treatment on some cardiovascular risk factors
and showed that exenatide had favorable effects on lipid
profile, hsCRP, NAFLD, CIMT, visceral adiposity, and
subcutaneous adiposity.
We observed significant improvement in glucose
control, with a significant reduction of HbA1c and fasting
blood glucose from baseline. This was consistent with the
existing literature [17]. Additionally, exenatide treatment
was associated with a significant reduction of triglyceride,
LDL, non-HDL cholesterol, and a significant increase
in HDL cholesterol levels. Studies showed increases in
HDL levels, but the effect of exenatide on LDL varies in
different studies [9,11,18]. Our study showed statistically
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significant decreases in LDL and non-HDL cholesterol.
The discrepancy may be due to patient selection. Our
study included only obese patients whose BMI was over
35 kg/m2.
Weight reduction is a well-known effect of exenatide
[7,17,19]. Abdominal adipose tissue consists of visceral
and subcutaneous adipose tissues, which have different
functions [9]. Visceral adipose tissue is an important
cardiovascular risk factor and also considered bad fat
[9,20]. Computed tomography (CT), magnetic resonance
imaging, and US are the methods used for measuring
adiposity. Hirooka et al. showed that measuring visceral
fat volume with US had similar results with CT and may
be used effectively [16]. We used US in our study because
of the advantage of its low cost and because it had no side
effects. Our study showed statistically significant decreases
in both visceral fat volume and subcutaneous fat thickness.
Even when only patients with weight reduction less than
5% were included in the analysis, significant decreases
in visceral fat volume and subcutaneous fat thickness
persisted. Limited evidence is available about the effect of
exenatide on visceral adiposity. Using CT measurements,
Du et al. [9] showed that exenatide decreased visceral
adipose tissue without a statistically significant decrease
in subcutaneous fat volume. They also mentioned that
the visceral/subcutaneous fat volume decreased with
exenatide [9]. This was not in accordance with our findings
because we found statistically significant decreases in both
visceral and subcutaneous fat tissues and, furthermore, the
decrease of subcutaneous fat thickness was more apparent.
The visceral fat volume/subcutaneous fat thickness ratio
increased significantly. To the best of our knowledge,
our study showed for the first time that the visceral/
subcutaneous fat ratio increases with exenatide therapy.
Our study included only obese patients over BMI of 35
kg/m2, and our findings should be supported with further
studies with broad selection criteria. In our study group,
hsCRP, which is also a cardiovascular risk factor, decreased

KÖSEOĞLU et al. / Turk J Med Sci

Figure Values of subcutaneous fat thickness (a); visceral fat volume (b); liver largest craniocaudal diameter (c), and carotid intima
media thickness (d), before and after exenatide treatment.

after 6 months of exenatide therapy. The reduction of
hsCRP with exenatide was previously reported on, and our
study supports this finding [15]
NAFLD, T2DM, and obesity are commonly seen
simultaneously in patients, and the prevalence of NAFLD
reaches 75% in patients with T2DM [21]. Patients with
NAFLD are at an increased risk for cardiovascular events
[22,23]. Because NAFLD is an important cardiovascular
risk factor, it is important to treat it. However, the treatment
of NAFLD remains inadequate, and it is generally directed
towards weight loss and comorbidity treatment [24]. GLP-1
receptor agonists have potential beneficial effects on NAFLD.
Liraglutide, a GLP-1 receptor agonist, has beneficial effects
on NAFLD, as well [25,26]. Exenatide has not been widely
investigated in patients with NAFLD and T2DM, and few
studies have shown the promising effects of exenatide on
NAFLD [10,27]. We showed in our trial that AST, ALT, and
GGT levels decreased with exenatide treatment; we also
showed that the liver craniocaudal diameter significantly

decreased with exenatide treatment. Furthermore, the
decrease of liver diameter was not correlated with weight
reduction and HbA1c reduction. US is a first step in the
evaluation of NAFLD but has no effectiveness in differentiating
NAFLD from nonalcoholic steatohepatitis (NASH). The liver
biopsy is still the gold standard for evaluating NAFLD and
NASH, but it has disadvantages, including cost, sampling
error, inter–observer variability, and procedure-related
complications [28]. The sensitivity of US on NAFLD is low,
but the specificity of US in predicting NAFLD was found to
be 94% in a metaanalysis [29]. A limitation of our study is the
lack of a liver biopsy, but obtaining a liver biopsy is beyond
the aim of this study. This limitation prevented in giving
strong advice about the use of exenatide on NAFLD, but our
findings may be a guide for further studies. A further study
with a liver biopsy before and after exenatide therapy may
show clinical benefits more clearly.
CIMT is a marker of atherosclerosis and predicts
cardiovascular events [12,30]. CIMT is a noninvasive and
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Table 3. Correlation analysis of the changes of HbA1c, weight, CIMT, subcutaneous fat thickness, and visceral fat volume.
ΔCIMT
ΔCIMT

ΔSubcutaneous fat
thickness

ΔVisceral fat
volume

ΔHbA1c

Δweight

Δliver diameter

r : 0.262
P : 0.099

r : 0.384
P : 0.013

r : 0.214
P : 0.173

r : 0.130
P : 0.405

r : -0.055 P :
0.724

r : 0.486
P : 0.001

r : 0.227
P : 0.170

r : 0.395
P : 0.013

r : 0.434
P : 0.002

r : 0.155
P : 0.353

r : 0.373
P : 0.019

r : 0.252
P : 0.087

r : 0.486
P : 0.001

r : 0.222
P : 0.164

ΔSubcutaneous fat
thickness

r : 0.262
P : 0.099

ΔVisceral fat volume

r : 0.384 P :
0.013

r : 0.486
P : 0.001

ΔHbA1c

r : 0.214 P :
0.173

r : 0.227
P : 0.170

r : 0.155
P : 0.353

ΔWeight

r : 0.130
P : 0.405

r : 0.395
P : 0.013

r : 0.373
P : 0.019

r : 0.486
P : 0.001

ΔLiver diameter

r : -0.055 P :
0.724

r : 0.434
P : 0.002

r : 0.252
P : 0.087

r : 0.222
P : 0.164

r : 0.225
P : 0.146
r : 0.225
P : 0.146

CIMT: carotid intima-media thickness; HbA1c: glycated hemoglobin.

effective method predicting atherosclerosis, and it is easily
measured with ultrasonography. Recently, it was shown
that administering exenatide once weekly improved
CIMT for the first time in the literature [14]. A more
recently published study showed that exenatide treatment
could prevent atherosclerosis progression in patients with
T2DM, compared to insulin therapy [31]. We showed that
exenatide treatment for 6 months significantly decreased
CIMT in obese patients with T2DM. Moreover, the
reduction of CIMT did not correlate with HbA1c reduction
and weight reduction. The decrease of visceral fat volume
correlated with CIMT reduction, which also supports the
fact that visceral fat predicts cardiovascular risk [32]. The
potential effect of exenatide on such cardiovascular risk
parameters may be varied. Obesity is in accordance with
CIMT, and weight reduction may be a reason for the CIMT
reduction in our study [33]. However, our study showed
no correlation between weight reduction and CIMT
reduction, and even patients with less weight reduction
had a significant decrease in CIMT. These findings suggest
that mechanisms other than weight reduction also have
effects on the decrease of CIMT. It has been shown that
exenatide reduces oxidative stress and has beneficial effects
on antioxidant enzymes in human in vitro monocytes/
macrophages [34]. Another study showed that exenatide
improved diastolic function and reduced arterial wall
stiffness [35]. Further studies are needed to show the exact
mechanism of exenatide on CIMT and atherosclerosis.
Our study included only obese patients with a BMI
over 35 kg/m2 because of the national health care system
reimbursement conditions. This is a limitation of our
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study, and our findings cannot be generalized to the whole
population. Studies including patients with a BMI less
than 35 kg/m2 should be performed to assess our finding
in the general population with T2DM. However, this
limitation is also a positive aspect of the study because it
may provide for the strong statistical findings in our study
group. Another limitation is the study duration; a longer
study duration could have resulted in more beneficial
results, but the limitations do not hinder our positive
results. The strengths of this study include the real world
setting, blinded measurements of CIMT, liver diameter,
and visceral and subcutaneous fat measurements.
5. Conclusion
Our study showed that 6 months of exenatide treatment
has beneficial effects on lipid profile, visceral fat volume,
NAFLD, CIMT, and hsCRP, which are all important
cardiovascular risk factors. Our study showed for the first
time in the literature that exenatide reduces both visceral
fat volume and subcutaneous fat thickness. We showed
that exenatide has favorable effects on NAFLD beyond
weight reduction.
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